UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

The real-world outcomes of multiple myeloma patients treated with daratumumab

PloS one, 2021-10, Vol.16 (10), p.e0258487-e0258487

2021

Volltextzugriff (PDF)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio

Blood cancer journal (New York), 2021-04, Vol.11 (4), p.70-70, Article 70

2021

Volltextzugriff (PDF)

P875: REPLACING STEROIDS IN TRANSPLANT‐INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB‐BORTEZOMIB‐LENALIDOMIDE‐DEXAMETHASONE REST STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e32161f4-n/a

2023

Volltextzugriff (PDF)

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

EJHaem, 2023-11, Vol.4 (4), p.1006-1012

2023

Volltextzugriff (PDF)

Synergy of two human endogenous retroviruses in multiple myeloma

Leukemia research, 2015-10, Vol.39 (10), p.1125-1128

2015

Volltextzugriff (PDF)

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Molecular oncology, 2018-02, Vol.12 (2), p.180-195

2018

Volltextzugriff (PDF)

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Blood, 2022-11, Vol.140 (Supplement 1), p.12623-12625

2022

Volltextzugriff (PDF)

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries

European journal of haematology, 2022-02, Vol.108 (2), p.99-108

2022

Volltextzugriff (PDF)

The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.3779-3779

2021

Volltextzugriff (PDF)

P-318 The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S213-S213

2023

Volltextzugriff (PDF)

Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation

European journal of haematology, 2023-03, Vol.110 (3), p.289-295

2023

Volltextzugriff (PDF)

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy

American journal of hematology, 2022-03, Vol.97 (3), p.E117-E120

2022

Volltextzugriff (PDF)

Patient heterogeneity in phase II studies of refractory disease in multiple myeloma – the ‘spell’ of the time to first relapse

British journal of haematology, 2008-01, Vol.140 (1), p.115-116

2008

Volltextzugriff (PDF)

P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S109-S110

2021

Volltextzugriff (PDF)

Creating Terroir: An Anthropological Perspective on New Nordic Cuisine as an Expression of Nordic Identity

Anthropology of food, 2012-12 (S7)

Hermansen, Mark Emil Tholstrup

2012

Volltextzugriff (PDF)

CD 138 + cell separation affects cancer gene expression in human myeloma cell lines

European journal of haematology, 2013-08, Vol.91 (2), p.187-188

2013

Volltextzugriff (PDF)

Creating Terroir

Anthropology of food, 2012

Hermansen, Mark Emil Tholstrup

2012

Volltextzugriff (PDF)

CD138+ cell separation affects cancer gene expression in human myeloma cell lines

European journal of haematology, 2013-08, Vol.91 (2), p.187-188

2013

Volltextzugriff (PDF)

Disseminated fusariosis in a patient with acute lymphoblastic leukaemia

Ugeskrift for læger, 2008-09, Vol.170 (37), p.2892

2008

Volltextzugriff (PDF)

Diagnosis and mortality of emergency department patients in the North Denmark region

BMC health services research, 2018-07, Vol.18 (1), p.548-9, Article 548

2018

Volltextzugriff (PDF)

Eastern Orthodox Perspectives on Violence

Religion and Violence, 2017, p.73-91

2017

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(24)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The real-world outcomes of multiple myeloma patients treated with daratumumab

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio

P875: REPLACING STEROIDS IN TRANSPLANT‐INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB‐BORTEZOMIB‐LENALIDOMIDE‐DEXAMETHASONE REST STUDY

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

Synergy of two human endogenous retroviruses in multiple myeloma

Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy

P-318 The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy

Patient heterogeneity in phase II studies of refractory disease in multiple myeloma – the ‘spell’ of the time to first relapse

P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

Creating Terroir: An Anthropological Perspective on New Nordic Cuisine as an Expression of Nordic Identity

CD 138 + cell separation affects cancer gene expression in human myeloma cell lines

Creating Terroir

CD138+ cell separation affects cancer gene expression in human myeloma cell lines

Disseminated fusariosis in a patient with acute lymphoblastic leukaemia

Nordic Food Culture

Diagnosis and mortality of emergency department patients in the North Denmark region

Eastern Orthodox Perspectives on Violence

Suchergebnisse filtern